Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165

ST Wrobleski, R Moslin, S Lin, Y Zhang… - Journal of Medicinal …, 2019 - ACS Publications
Small molecule JAK inhibitors have emerged as a major therapeutic advancement in
treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that …
被引用次数：270 相关文章

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.

ST Wrobleski, R Moslin, S Lin, Y Zhang… - Journal of Medicinal …, 2019 - europepmc.org
Small molecule JAK inhibitors have emerged as a major therapeutic advancement in
treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that …

[引用][C] Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

ST Wrobleski, R Moslin, S Lin, Y Zhang, S Spergel… - J. Med. Chem., 2020 - osti.gov

[引用][C] Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

ST Wrobleski, R Moslin, S Lin, Y Zhang… - Journal of Medicinal …, 2019 - cir.nii.ac.jp
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune
Diseases: Discovery of the Allosteric Inhibitor BMS-986165 | CiNii Research CiNii 国立情報学 …

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

ST Wrobleski, R Moslin, S Lin… - Journal of …, 2019 - pubmed.ncbi.nlm.nih.gov
Small molecule JAK inhibitors have emerged as a major therapeutic advancement in
treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that …